Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

CD8 T cells targeting adapted epitopes in chronic HIV infection promote dendritic cell maturation and CD4 T cell trans-infection.

Qin K, Boppana S, Du VY, Carlson JM, Yue L, Dilernia DA, Hunter E, Mailliard RB, Mallal SA, Bansal A, Goepfert PA.

PLoS Pathog. 2019 Aug 9;15(8):e1007970. doi: 10.1371/journal.ppat.1007970. eCollection 2019 Aug.

2.

HLA-I Associated Adaptation Dampens CD8 T-Cell Responses in HIV Ad5-Vectored Vaccine Recipients.

Boppana S, Sterrett S, Files J, Qin K, Fiore-Gartland A, Cohen KW, De Rosa SC, Bansal A, Goepfert PA.

J Infect Dis. 2019 Oct 8;220(10):1620-1628. doi: 10.1093/infdis/jiz368.

PMID:
31301135
3.

Understanding the CD8 T-cell response in natural HIV control.

Boppana S, Goepfert P.

F1000Res. 2018 Jul 2;7. pii: F1000 Faculty Rev-985. doi: 10.12688/f1000research.15029.1. eCollection 2018. Review.

4.

Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection.

Peng BJ, Carlson JM, Liu MKP, Gao F, Goonetilleke N, McMichael AJ, Borrow P, Gilmour J, Heath SL, Hunter E, Bansal A, Goepfert PA.

J Virol. 2018 Sep 12;92(19). pii: e00711-18. doi: 10.1128/JVI.00711-18. Print 2018 Oct 1.

5.

Progressive lentivirus infection induces natural killer cell receptor-expressing B cells in the gastrointestinal tract.

Manickam C, Nwanze C, Ram DR, Shah SV, Smith S, Jones R, Hueber B, Kroll K, Varner V, Goepfert P, Jost S, Reeves RK.

AIDS. 2018 Jul 31;32(12):1571-1578. doi: 10.1097/QAD.0000000000001855.

6.

Short Communication: Apoptotic Membrane Microparticles Quantified by Fluorescent Bead-Based Assay Are Elevated in HIV and SIV Infections.

Autissier E, Li H, Goepfert PA, Reeves RK.

AIDS Res Hum Retroviruses. 2018 May;34(5):446-448. doi: 10.1089/AID.2018.0011. Epub 2018 Mar 27.

7.

Immunogenetic factors in early immune control of human immunodeficiency virus type 1 (HIV-1) infection: Evaluation of HLA class I amino acid variants in two African populations.

Wiener HW, Shrestha S, Lu H, Karita E, Kilembe W, Allen S, Hunter E, Goepfert PA, Tang J.

Hum Immunol. 2018 Mar;79(3):166-171. doi: 10.1016/j.humimm.2017.12.005. Epub 2017 Dec 28.

8.

CD151 Expression Is Associated with a Hyperproliferative T Cell Phenotype.

Seu L, Tidwell C, Timares L, Duverger A, Wagner FH, Goepfert PA, Westfall AO, Sabbaj S, Kutsch O.

J Immunol. 2017 Nov 1;199(9):3336-3347. doi: 10.4049/jimmunol.1700648. Epub 2017 Sep 27.

9.

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.

Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody MA, Frahm N, Montefiori DC, Hay CM, Goepfert PA, Baden LR, Robinson HL, Yu X, Gilbert PB, McElrath MJ, Huang Y, Tomaras GD; HIV Vaccine Trials Network (HVTN) 094 Study Group.

PLoS One. 2017 Jul 20;12(7):e0179597. doi: 10.1371/journal.pone.0179597. eCollection 2017.

10.

CD4+ T cells from HIV-1 patients with impaired Th1 effector responses to Mycobacterium tuberculosis exhibit diminished histone and nucleoprotein signatures.

Seu L, Mobley JA, Goepfert PA.

Clin Immunol. 2017 Aug;181:16-23. doi: 10.1016/j.clim.2017.05.018. Epub 2017 May 25.

11.

Diminished CD103 (αEβ7) Expression on Resident T Cells from the Female Genital Tract of HIV-Positive Women.

Moylan DC, Goepfert PA, Kempf MC, Saag MS, Richter HE, Mestecky J, Sabbaj S.

Pathog Immun. 2016 Fall-Winter;1(2):371-387. doi: 10.20411/pai.v1i2.166. Epub 2017 Jan 16.

12.

Dysregulation of Systemic and Mucosal Humoral Responses to Microbial and Food Antigens as a Factor Contributing to Microbial Translocation and Chronic Inflammation in HIV-1 Infection.

Hel Z, Xu J, Denning WL, Helton ES, Huijbregts RP, Heath SL, Overton ET, Christmann BS, Elson CO, Goepfert PA, Mestecky J.

PLoS Pathog. 2017 Jan 26;13(1):e1006087. doi: 10.1371/journal.ppat.1006087. eCollection 2017 Jan.

13.

Use of Dried Blood Spots to Elucidate Full-Length Transmitted/Founder HIV-1 Genomes.

Salazar-Gonzalez JF, Salazar MG, Tully DC, Ogilvie CB, Learn GH, Allen TM, Heath SL, Goepfert P, Bar KJ.

Pathog Immun. 2016 Spring;1(1):129-153.

14.

Dynamics and Correlates of CD8 T-Cell Counts in Africans with Primary Human Immunodeficiency Virus Type 1 Infection.

Prentice HA, Lu H, Price MA, Kamali A, Karita E, Lakhi S, Sanders EJ, Anzala O, Allen S, Goepfert PA, Hunter E, Gilmour J, Tang J.

J Virol. 2016 Oct 28;90(22):10423-10430. doi: 10.1128/JVI.01467-16. Print 2016 Nov 15.

15.

Balance between transmitted HLA preadapted and nonassociated polymorphisms is a major determinant of HIV-1 disease progression.

Mónaco DC, Dilernia DA, Fiore-Gartland A, Yu T, Prince JL, Dennis KK, Qin K, Schaefer M, Claiborne DT, Kilembe W, Tang J, Price MA, Farmer P, Gilmour J, Bansal A, Allen S, Goepfert P, Hunter E.

J Exp Med. 2016 Sep 19;213(10):2049-63. doi: 10.1084/jem.20151984. Epub 2016 Aug 22.

16.

Impact of pre-adapted HIV transmission.

Carlson JM, Du VY, Pfeifer N, Bansal A, Tan VY, Power K, Brumme CJ, Kreimer A, DeZiel CE, Fusi N, Schaefer M, Brockman MA, Gilmour J, Price MA, Kilembe W, Haubrich R, John M, Mallal S, Shapiro R, Frater J, Harrigan PR, Ndung'u T, Allen S, Heckerman D, Sidney J, Allen TM, Goulder PJ, Brumme ZL, Hunter E, Goepfert PA.

Nat Med. 2016 Jun;22(6):606-13. doi: 10.1038/nm.4100. Epub 2016 May 16.

17.

HIV-1-Specific CD8 T Cells Exhibit Limited Cross-Reactivity during Acute Infection.

Du VY, Bansal A, Carlson J, Salazar-Gonzalez JF, Salazar MG, Ladell K, Gras S, Josephs TM, Heath SL, Price DA, Rossjohn J, Hunter E, Goepfert PA.

J Immunol. 2016 Apr 15;196(8):3276-86. doi: 10.4049/jimmunol.1502411. Epub 2016 Mar 16.

18.

HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells.

Chan CN, Trinité B, Lee CS, Mahajan S, Anand A, Wodarz D, Sabbaj S, Bansal A, Goepfert PA, Levy DN.

Retrovirology. 2016 Jan 5;13:1. doi: 10.1186/s12977-015-0234-9.

19.

Brief Report: Enhanced Allogeneic Cellular Responses to Mismatched HLA-B Antigens Results in More Efficient Killing of HIV Infected Cells.

Sabbaj S, Scanlon N, Du VY, Wang Y, Tang J, Hunter E, Goepfert PA.

J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):493-7. doi: 10.1097/QAI.0000000000000901.

20.

Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.

Fuchs JD, Bart PA, Frahm N, Morgan C, Gilbert PB, Kochar N, DeRosa SC, Tomaras GD, Wagner TM, Baden LR, Koblin BA, Rouphael NG, Kalams SA, Keefer MC, Goepfert PA, Sobieszczyk ME, Mayer KH, Swann E, Liao HX, Haynes BF, Graham BS, McElrath MJ; NIAID HIV Vaccine Trials Network.

J AIDS Clin Res. 2015 May;6(5). pii: 461. Epub 2015 May 23.

21.

Normal T-cell activation in elite controllers with preserved CD4+ T-cell counts.

Bansal A, Sterrett S, Erdmann N, Westfall AO, Dionne-Odom J, Overton ET, Goepfert PA.

AIDS. 2015 Nov;29(17):2245-54. doi: 10.1097/QAD.0000000000000860.

22.

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X; HVTN 083 Study Group and the NIAID HVTN.

J Infect Dis. 2016 Feb 15;213(4):541-50. doi: 10.1093/infdis/jiv496. Epub 2015 Oct 15.

23.

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.

Overton ET, Stapleton J, Frank I, Hassler S, Goepfert PA, Barker D, Wagner E, von Krempelhuber A, Virgin G, Meyer TP, Müller J, Bädeker N, Grünert R, Young P, Rösch S, Maclennan J, Arndtz-Wiedemann N, Chaplin P.

Open Forum Infect Dis. 2015 May 5;2(2):ofv040. doi: 10.1093/ofid/ofv040. eCollection 2015 Apr. Erratum in: Open Forum Infect Dis. 2016 Jan;3(1):ofv183.

24.

Enhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome.

Bansal A, Mann T, Sterrett S, Peng BJ, Bet A, Carlson JM, Goepfert PA.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):1-8. doi: 10.1097/QAI.0000000000000700.

25.

HLA Class-II Associated HIV Polymorphisms Predict Escape from CD4+ T Cell Responses.

Erdmann N, Du VY, Carlson J, Schaefer M, Jureka A, Sterrett S, Yue L, Dilernia D, Lakhi S, Tang J, Sidney J, Gilmour J, Allen S, Hunter E, Heath S, Bansal A, Goepfert PA.

PLoS Pathog. 2015 Aug 24;11(8):e1005111. doi: 10.1371/journal.ppat.1005111. eCollection 2015 Aug.

26.

Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection.

Seu L, Sabbaj S, Duverger A, Wagner F, Anderson JC, Davies E, Wolschendorf F, Willey CD, Saag MS, Goepfert P, Kutsch O.

J Virol. 2015 Jul;89(13):6656-72. doi: 10.1128/JVI.00571-15. Epub 2015 Apr 15.

27.

The HIV-1 antisense protein (ASP) induces CD8 T cell responses during chronic infection.

Bet A, Maze EA, Bansal A, Sterrett S, Gross A, Graff-Dubois S, Samri A, Guihot A, Katlama C, Theodorou I, Mesnard JM, Moris A, Goepfert PA, Cardinaud S.

Retrovirology. 2015 Feb 10;12:15. doi: 10.1186/s12977-015-0135-y.

28.

Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression.

Claiborne DT, Prince JL, Scully E, Macharia G, Micci L, Lawson B, Kopycinski J, Deymier MJ, Vanderford TH, Nganou-Makamdop K, Ende Z, Brooks K, Tang J, Yu T, Lakhi S, Kilembe W, Silvestri G, Douek D, Goepfert PA, Price MA, Allen SA, Paiardini M, Altfeld M, Gilmour J, Hunter E.

Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):E1480-9. doi: 10.1073/pnas.1421607112. Epub 2015 Feb 17.

29.

Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4.

Stoddard MB, Li H, Wang S, Saeed M, Andrus L, Ding W, Jiang X, Learn GH, von Schaewen M, Wen J, Goepfert PA, Hahn BH, Ploss A, Rice CM, Shaw GM.

MBio. 2015 Feb 24;6(2):e02518. doi: 10.1128/mBio.02518-14.

30.

Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.

Overton ET, Sterrett S, Westfall AO, Kahan SM, Burkholder G, Zajac AJ, Goepfert PA, Bansal A.

AIDS. 2014 Nov 13;28(17):2627-2631. doi: 10.1097/QAD.0000000000000475.

31.

Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients.

Yue L, Pfafferott KJ, Baalwa J, Conrod K, Dong CC, Chui C, Rong R, Claiborne DT, Prince JL, Tang J, Ribeiro RM, Cormier E, Hahn BH, Perelson AS, Shaw GM, Karita E, Gilmour J, Goepfert P, Derdeyn CA, Allen SA, Borrow P, Hunter E.

PLoS Pathog. 2015 Jan 8;11(1):e1004565. doi: 10.1371/journal.ppat.1004565. eCollection 2015 Jan.

32.

Short communication: Plasmacytoid dendritic cells from HIV-1 Elite Controllers maintain a gut-homing phenotype associated with immune activation.

Li H, Goepfert P, Reeves RK.

AIDS Res Hum Retroviruses. 2014 Dec;30(12):1213-5. doi: 10.1089/aid.2014.0174.

PMID:
25387330
33.

Human immunodeficiency virus vaccines.

Goepfert P, Bansal A.

Infect Dis Clin North Am. 2014 Dec;28(4):615-31. doi: 10.1016/j.idc.2014.08.004. Epub 2014 Oct 5. Review.

34.

Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals.

Bharaj P, Chahar HS, Alozie OK, Rodarte L, Bansal A, Goepfert PA, Dwivedi A, Manjunath N, Shankar P.

PLoS One. 2014 Oct 3;9(10):e109103. doi: 10.1371/journal.pone.0109103. eCollection 2014.

35.

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Frey SE, Peiperl L, McElrath MJ, Kalams S, Goepfert PA, Keefer MC, Baden LR, Lally MA, Mayer K, Blattner WA, Harro CD, Hammer SM, Gorse GJ, Hural J, Tomaras GD, Levy Y, Gilbert P, deCamp A, Russell ND, Elizaga M, Allen M, Corey L.

Clin Vaccine Immunol. 2014 Nov;21(11):1589-99. doi: 10.1128/CVI.00450-14. Epub 2014 Sep 24.

36.

Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.

Overton ET, Goepfert PA, Cunningham P, Carter WA, Horvath J, Young D, Strayer DR.

Vaccine. 2014 Sep 22;32(42):5490-5. doi: 10.1016/j.vaccine.2014.07.078. Epub 2014 Aug 13.

PMID:
25128802
37.

HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck.

Carlson JM, Schaefer M, Monaco DC, Batorsky R, Claiborne DT, Prince J, Deymier MJ, Ende ZS, Klatt NR, DeZiel CE, Lin TH, Peng J, Seese AM, Shapiro R, Frater J, Ndung'u T, Tang J, Goepfert P, Gilmour J, Price MA, Kilembe W, Heckerman D, Goulder PJ, Allen TM, Allen S, Hunter E.

Science. 2014 Jul 11;345(6193):1254031. doi: 10.1126/science.1254031. Epub 2014 Jul 10.

38.

Immune activation is associated with CD8 T cell interleukin-21 production in HIV-1-infected individuals.

Williams LD, Amatya N, Bansal A, Sabbaj S, Heath SL, Sereti I, Goepfert PA.

J Virol. 2014 Sep 1;88(17):10259-63. doi: 10.1128/JVI.00764-14. Epub 2014 Jun 18.

39.

KIR2DS4 promotes HIV-1 pathogenesis: new evidence from analyses of immunogenetic data and natural killer cell function.

Merino AM, Dugast AS, Wilson CM, Goepfert PA, Alter G, Kaslow RA, Tang J.

PLoS One. 2014 Jun 5;9(6):e99353. doi: 10.1371/journal.pone.0099353. eCollection 2014.

40.

Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway.

Bowers NL, Helton ES, Huijbregts RP, Goepfert PA, Heath SL, Hel Z.

PLoS Pathog. 2014 Mar 13;10(3):e1003993. doi: 10.1371/journal.ppat.1003993. eCollection 2014 Mar.

41.

Characterization of T-cell responses to cryptic epitopes in recipients of a noncodon-optimized HIV-1 vaccine.

Bet A, Sterrett S, Sato A, Bansal A, Goepfert PA.

J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):142-50. doi: 10.1097/QAI.0b013e3182a9917e.

42.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder SP, Hammer SM, Koblin BA, Pensiero M, Butler C, Moss B, Robinson HL; HVTN 205 Study Group; National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network.

J Infect Dis. 2014 Jul 1;210(1):99-110. doi: 10.1093/infdis/jiu003. Epub 2014 Jan 7.

43.

Dimorphic HLA-B signal peptides differentially influence HLA-E- and natural killer cell-mediated cytolysis of HIV-1-infected target cells.

Merino AM, Sabbaj S, Easlick J, Goepfert P, Kaslow RA, Tang J.

Clin Exp Immunol. 2013 Dec;174(3):414-23. doi: 10.1111/cei.12187.

44.

Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.

Murphy MK, Yue L, Pan R, Boliar S, Sethi A, Tian J, Pfafferot K, Karita E, Allen SA, Cormier E, Goepfert PA, Borrow P, Robinson JE, Gnanakaran S, Hunter E, Kong XP, Derdeyn CA.

PLoS Pathog. 2013 Feb;9(2):e1003173. doi: 10.1371/journal.ppat.1003173. Epub 2013 Feb 28.

45.

HIV-specific CD8+ T cells from elite controllers are primed for survival.

Yan J, Sabbaj S, Bansal A, Amatya N, Shacka JJ, Goepfert PA, Heath SL.

J Virol. 2013 May;87(9):5170-81. doi: 10.1128/JVI.02379-12. Epub 2013 Feb 28.

46.

Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms.

Huijbregts RP, Helton ES, Michel KG, Sabbaj S, Richter HE, Goepfert PA, Hel Z.

Endocrinology. 2013 Mar;154(3):1282-95. doi: 10.1210/en.2012-1850. Epub 2013 Jan 25.

47.

Comparative Evaluation of HIV-1 Neutralization in External Secretions and Sera of HIV-1-Infected Women.

Wei Q, Moldoveanu Z, Huang WQ, Alexander RC, Goepfert PA, Mestecky J.

Open AIDS J. 2012;6:293-302. doi: 10.2174/1874613601206010293. Epub 2012 Dec 28.

48.

Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis.

Prince JL, Claiborne DT, Carlson JM, Schaefer M, Yu T, Lahki S, Prentice HA, Yue L, Vishwanathan SA, Kilembe W, Goepfert P, Price MA, Gilmour J, Mulenga J, Farmer P, Derdeyn CA, Tang J, Heckerman D, Kaslow RA, Allen SA, Hunter E.

PLoS Pathog. 2012;8(11):e1003041. doi: 10.1371/journal.ppat.1003041. Epub 2012 Nov 29.

49.

Cumulative impact of host and viral factors on HIV-1 viral-load control during early infection.

Yue L, Prentice HA, Farmer P, Song W, He D, Lakhi S, Goepfert P, Gilmour J, Allen S, Tang J, Kaslow RA, Hunter E.

J Virol. 2013 Jan;87(2):708-15. doi: 10.1128/JVI.02118-12. Epub 2012 Oct 31.

50.

MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.

Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, Wolfson J, Hertz T, Kallas E, Goepfert P, Friedrich DP, Corey L, Mullins JI, McElrath MJ, Gilbert P.

PLoS One. 2012;7(8):e43396. doi: 10.1371/journal.pone.0043396. Epub 2012 Aug 27.

Supplemental Content

Loading ...
Support Center